Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
MIST 
Milestone Pharmaceuticals Inc (MIST)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: MIST (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -62.86% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 40.55M USD | Price to earnings Ratio - | 1Y Target Price 5 |
Price to earnings Ratio - | 1Y Target Price 5 | ||
Volume (30-day avg) 3653473 | Beta 1.84 | 52 Weeks Range 0.72 - 2.75 | Updated Date 04/1/2025 |
52 Weeks Range 0.72 - 2.75 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.67 |
Earnings Date
Report Date 2025-03-19 | When Before Market | Estimate -0.15 | Actual -0.19 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -34.92% | Return on Equity (TTM) -277.55% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 35463076 | Price to Sales(TTM) 77.32 |
Enterprise Value 35463076 | Price to Sales(TTM) 77.32 | ||
Enterprise Value to Revenue 81.44 | Enterprise Value to EBITDA -1.43 | Shares Outstanding 53354000 | Shares Floating 53004370 |
Shares Outstanding 53354000 | Shares Floating 53004370 | ||
Percent Insiders 0.66 | Percent Institutions 46.69 |
Analyst Ratings
Rating 4 | Target Price 10.25 | Buy 2 | Strong Buy 1 |
Buy 2 | Strong Buy 1 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Milestone Pharmaceuticals Inc
Company Overview
History and Background
Milestone Pharmaceuticals Inc., founded in 2003, is a biopharmaceutical company focused on developing and commercializing etripamil for cardiovascular indications. It has focused primarily on developing therapies for paroxysmal supraventricular tachycardia (PSVT).
Core Business Areas
- Pharmaceutical Development: Focuses on developing and commercializing novel cardiovascular therapies, primarily etripamil.
Leadership and Structure
The company is led by a management team with experience in cardiovascular drug development and commercialization. Board of Directors provides oversight.
Top Products and Market Share
Key Offerings
- Etripamil: Etripamil is Milestone's investigational product for the treatment of PSVT. The market is fragmented, and estimating precise market share is difficult given the pre-commercial status. Competitors include existing adenosine and calcium channel blockers. Future data is needed to determine market share after regulatory approval is obtained by Milestone.
Market Dynamics
Industry Overview
The cardiovascular therapeutics market is large and growing, driven by an aging population and increasing prevalence of cardiovascular diseases.
Positioning
Milestone aims to address an unmet need in the treatment of PSVT with a self-administered nasal spray formulation of etripamil, offering a more convenient and potentially faster-acting alternative to current therapies.
Total Addressable Market (TAM)
The PSVT market represents a significant TAM. Etripamil is designed for ease of use outside of a healthcare facility to address acute episodes. Milestone Pharmaceutical's Etripamil is currently in phase III clinical trials, therefore the size of the market and Milestoneu2019s ability to capture it is still undetermined.
Upturn SWOT Analysis
Strengths
- Novel drug candidate (Etripamil) with a potentially improved route of administration
- Focus on a specific and addressable cardiovascular indication (PSVT)
- Experienced management team
Weaknesses
- Reliance on a single lead product candidate
- Need to obtain regulatory approval
- Commercialization risks
- High cash burn rate
Opportunities
- Potential for market exclusivity upon regulatory approval
- Expansion into other cardiovascular indications
- Partnerships or acquisitions to broaden product portfolio
Threats
- Regulatory setbacks or delays
- Competition from existing and emerging therapies
- Failure to demonstrate clinical efficacy
- Patent challenges
Competitors and Market Share
Key Competitors
- BMY
- PFE
- MRK
Competitive Landscape
Milestone aims to compete with existing PSVT treatments by offering a more convenient and potentially faster-acting alternative, which can improve the patient's quality of life.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Milestone's growth is tied to the development and commercialization of etripamil. It is currently a pre-revenue company.
Future Projections: Future growth depends on successful clinical trials, regulatory approval, and commercial launch of etripamil. Analyst estimates vary depending on assumptions about these factors.
Recent Initiatives: Recent initiatives include completing and reporting results from clinical trials for etripamil.
Summary
Milestone Pharmaceuticals is a development-stage company focused on etripamil for PSVT, a novel approach with a potentially large market. Its success hinges on positive clinical trial outcomes, regulatory approvals, and successful commercialization. A key risk is the reliance on a single product candidate. However, if etripamil is successful, Milestone has a positive trajectory.
Similar Companies
- BMY
- PFE
- MRK
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Financial data and market conditions are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Milestone Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Montreal, QC, Canada | ||
IPO Launch date 2019-05-09 | CEO, President & Director Mr. Joseph G. Oliveto M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 33 | Website https://www.milestonepharma.com |
Full time employees 33 | Website https://www.milestonepharma.com | ||
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.